表紙
市場調査レポート

中国のアダリムマブ市場の分析

Investigation Report on China Adalimumab Market, 2010-2018

発行 China Research and Intelligence 商品コード 297271
出版日 ページ情報 英文 40 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=107.50円で換算しております。
Back to Top
中国のアダリムマブ市場の分析 Investigation Report on China Adalimumab Market, 2010-2018
出版日: 2014年03月06日 ページ情報: 英文 40 Pages
概要

アダリムマブは腫瘍壊死因子(TNF)を阻害する抗炎症剤で、米国FDA(食品医薬品局)が最初に認証した完全ヒトモノクローナル抗体です。2008年にAbbott(現:AbbVie)より「Humira」という商品名でFDAの認証を獲得し、以後世界各国で急速に売上高を拡大しています。中国でも2010年に上市され、2010〜2013年に売上高が20倍も拡大しました。一方で、2016年には「Humira」の特許が失効となるため、中国企業の中にはジェネリック医薬品の開発に挑もうとする動きも出てきています。

当レポートでは、中国におけるアダリムマブの市場について分析し、中国国内での生産高および病院向け売上高・価格の動向(過去5年間分)、企業別・投薬形態別の市場シェア、将来的な市場動向の見通し(今後5年間分)などを調査して、その結果を概略以下の構成でお届けします。

第1章 アダリムマブの関連概念

  • 進行過程と症状
  • 世界市場での販売状況

第2章 中国のアダリムマブ市場の概要

  • 特許の現状
  • 主要メーカー
  • 市場規模

第3章 アダリムマブの売上高の分析

  • 総売上高
  • 地域別の売上高

第4章 主要メーカーの市場シェアの分析

第5章 剤形別の市場規模の分析

第6章 アダリムマブの病院向け基準価格(企業別)

第7章 主要メーカーの分析

第8章 中国のアダリムマブ市場の将来展望

  • アダリムマブの適応症グループの見通し
  • ジェネリック医薬品の製造スケジュール
  • 市場規模の予測
  • 市場パターンの予測

図表一覧

目次
Product Code: 1403126

Adalimumab is a TNF (tumor necrosis factor) inhibiting anti-inflammatory drug, the first fully human monoclonal antibody drug approved by the FDA. It was discovered through collaboration between BASF Bioresearch Corporation and Cambridge Antibody Technology in 1993, then further manufactured at BASF Bioresearch Corporation and developed by BASF Knoll (BASF Pharma) and, ultimately, manufactured and marketed by Abbott Laboratories after the acquisition of BASF Pharma by Abbott. In 2000 Abbott Laboratories took over Knoll with USD 6.9 billion. At the end of 2002 adalimumab was approved to the market by FDA.

As of 2008 adalimumab (produced by Abbott with the trade name "Humira") had been approved by FDA for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, moderate to severe chronic psoriasis and juvenile idiopathic arthritis. Adalimumab is the best seller in the world in recent years. It can satisfy many urgent clinical needs because of its wide range of indications. The global sales revenue of Humira in 2012 exceeded USD 9 billion, and it reached USD 10 billion in 2013. Humira was launched in China in August 2010. According to CRI's market investigation, the sales revenue of adalimumab in Chinese sample hospitals grew 20 times from 2010 to 2013. More than 10 million people in China have adalimumab indications.

Humira is expected to bring Abbott (now AbbVie) the total sales revenue of USD 100 billion before its patent expires in 2016. This has made Humira the primary target of pharmaceutical enterprises from the world. More than 20 enterprises worldwide are developing adalimumab generic drugs and many of them are Chinese enterprises.

Huahai Pharmaceutical announced in May 2013 that they signed a strategic alliance agreement with ONCOBIOLOGICS to jointly develop biological drugs. The agreement states that Huahai Pharmaceutical is bestowed with 100% marketing right of four monoclonal antibody biological drugs in China. If Huahai Pharmaceutical establishes joint ventures in the U.S. to develop the four monoclonal antibody biological drugs, it will have 51% of the marketing right in developed countries such as the U.S. and Europe. Meanwhile the company will jointly establish a biopharmaceutical company with ONCOBIOLOGICS in China to develop monoclonal antibody biological drugs and conduct industrialization technique application research.

In December 2013 Huahai was informed by Oncobiologics that the MAb biosimilar Humira jointly developed was approved to launch phase I clinical trial by EMA (the European Medicines Agency) and FDA.

Duo to large market size, challenging R&D and high profit of the monoclonal antibody drug market, the collaboration between Huahai Pharmaceutical and Oncobiologics is praised by the industry as the "Second Transformation" supported by the international biopharmaceutical giant's strong R&D strength. The approval for adalimumab to launch phase I clinical trial means a significant progress of the collaboration.

However, follow-up R&D of the monoclonal antibody product requires a large amount of time before the product appears on the market. It is estimated that Abbott will continue to occupy the global market of adalimumab in the next few years. However, the situation will change gradually after 2017.

Through this report, the readers can acquire the following information:

  • Market Size of Adalimumab in China
  • Sales price of Adalimumab in Hospital Market in China
  • Price of Adalimumab Produced by Vetter Pharma Fertigung GmbH & Co. KG in China Hospital, 2014
  • Manufacturing Schedule of Adalimumab Generic Drug
  • Prospect of China Adalimumab Market

The following enterprises and people are recommended to purchase this report:

  • Manufacturers of Crude and Finished Monoclonal Antibody Remedy
  • Medical Institutions
  • Investors/Research Institutes Focusing on Monoclonal Antibody Market

Table of Contents

1. Relevant Concepts of Adalimumab

  • 1.1. Development Process and Indication
  • 1.2. Sales Status on the Global Market

2. Market Overview of Adalimumab in China, 2010-2013

  • 2.1. Patent Status
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Investigation on Sales Value of Adalimumab in China, 2010-2013

  • 3.1. Total Sales Value
  • 3.2. Sales Value by Region

4. Investigation on Market Share of Major Adalimumab Manufacturers in China, 2010-2013

5. Investigation on Market Size of Adalimumab by Dosage Form in China, 2010-2013

6. Reference Price of Adalimumab in China Adalimumab Hospital Market, 2013

7. Analysis on Major Adalimumab Manufacturers in China, 2010-2013

8. Prospect of China Adalimumab Market, 2014-2018

  • 8.1. Prospect of Adalimumab Indication Group
  • 8.2. Manufacturing Schedule of Generic Drug
  • 8.3. Forecast on Market Size
  • 8.4. Forecast on Competition Pattern

Selected Charts

  • Chart Adalimumab Products Approved to Market in China, 2014
  • Chart Forecast on Market Size of Hospital-use Adalimumab in China, 2014-2018
  • Chart Global Sales Value of Adalimumab, 2010-2013
  • Chart Sales Value of Adalimumab in China Hospital Market, 2010-2013
  • Chart Sales Value of Adalimumab by Region in China, 2010-2013
  • Chart Market Share of Adalimumab in China, 2010-2013
  • Chart Price of Adalimumab Produced by GENENTECH (US) in Hospital Market, 2010-2013
  • Chart Price of Adalimumab Produced by Shanghai Roche in Hospital Market, 2010-2013
Back to Top